Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET

Inclusion Criteria: * Female, age 30-42 years old. * Diagnosis of POR (2011 ESHRE Bologna Standard). * At least two previous IVF failure history. * Voluntarily to sign the "informed consent". Exclusion Criteria: * Severe acute and chronic liver and kidney disease，Such as liver cirrhosis, acute and chronic renal failure, hepatitis B virus activity period, etc.；Liver and kidney dysfunction. * Endocrine and metabolic diseases，eg, diabetes、Thyroid function hyperthyroidism, Thyroid dysfunction, cushing's syndrome, hyperprolactinemia，hyperandrogenism. * Related diseases affecting outcome of IVF pregnancy，eg, hydrosalpinx, hysteromyoma≥4cm, adenomyosis, stage III and IV endometriosis, untreated endometrial lesions, uterine malformation, genital tuberculosis, malignant tumor of reproductive system （include endometrial carcinoma, cervical carcinoma, ovarian cancer, fallopian tube carcinoma）. * Allergic to E. coli expression product and its excipients. * Subjects who participated in the past three months or are participating in other drug clinical researchers. * IVF failure history≥3. * The researchers consider who is not suitable for enrolling the group.